Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 18, 2023 (before its estimated March 2024 completion). Its status may not reflect the trial's current state.
Summary
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.
Trial Details
NCT Number NCT06041061
Lead Sponsor Sinocelltech Ltd.
Collaborators: Guangxi Center for Disease Control and Prevention, Henan Center for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Centers for Disease Control and Prevention, China, Yunnan Center for Disease Control and Prevention
Conditions HPV InfectioN, HPV-Related Carcinoma
Enrollment 18,000 participants
Start Date 2023-08-13
Primary Completion 2024-03 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2023-09-18